181 related articles for article (PubMed ID: 27781145)
1. The feasibility of
Sasaki K; Maikusa N; Imabayashi E; Yuasa T; Matsuda H
Brain Behav; 2016 Oct; 6(10):e00532. PubMed ID: 27781145
[TBL] [Abstract][Full Text] [Related]
2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
[TBL] [Abstract][Full Text] [Related]
3. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
[TBL] [Abstract][Full Text] [Related]
4. Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification.
Presotto L; Iaccarino L; Sala A; Vanoli EG; Muscio C; Nigri A; Bruzzone MG; Tagliavini F; Gianolli L; Perani D; Bettinardi V
Neuroimage Clin; 2018; 20():153-160. PubMed ID: 30094164
[TBL] [Abstract][Full Text] [Related]
5. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI.
Akamatsu G; Ikari Y; Ohnishi A; Nishida H; Aita K; Sasaki M; Yamamoto Y; Sasaki M; Senda M
Phys Med Biol; 2016 Aug; 61(15):5768-80. PubMed ID: 27405579
[TBL] [Abstract][Full Text] [Related]
6. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
7. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease.
Thomas BA; Erlandsson K; Modat M; Thurfjell L; Vandenberghe R; Ourselin S; Hutton BF
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1104-19. PubMed ID: 21336694
[TBL] [Abstract][Full Text] [Related]
8. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
9. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
Chen CD; Joseph-Mathurin N; Sinha N; Zhou A; Li Y; Friedrichsen K; McCullough A; Franklin EE; Hornbeck R; Gordon B; Sharma V; Cruchaga C; Goate A; Karch C; McDade E; Xiong C; Bateman RJ; Ghetti B; Ringman JM; Chhatwal J; Masters CL; McLean C; Lashley T; Su Y; Koeppe R; Jack C; Klunk WE; Morris JC; Perrin RJ; Cairns NJ; Benzinger TLS
Acta Neuropathol; 2021 Oct; 142(4):689-706. PubMed ID: 34319442
[TBL] [Abstract][Full Text] [Related]
10. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
11. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
[TBL] [Abstract][Full Text] [Related]
12. MR-less surface-based amyloid assessment based on 11C PiB PET.
Zhou L; Salvado O; Dore V; Bourgeat P; Raniga P; Macaulay SL; Ames D; Masters CL; Ellis KA; Villemagne VL; Rowe CC; Fripp J;
PLoS One; 2014; 9(1):e84777. PubMed ID: 24427295
[TBL] [Abstract][Full Text] [Related]
13. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
14. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
[TBL] [Abstract][Full Text] [Related]
15. Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment.
Brown EE; Rashidi-Ranjbar N; Caravaggio F; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Fischer CE; Flint A; Mah L; Herrmann N; Bowie CR; Voineskos AN; Graff-Guerrero A;
J Neuroimaging; 2019 Nov; 29(6):721-729. PubMed ID: 31270885
[TBL] [Abstract][Full Text] [Related]
16. PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET - Application to amyloid imaging with AV45-PET.
Gonzalez-Escamilla G; Lange C; Teipel S; Buchert R; Grothe MJ;
Neuroimage; 2017 Feb; 147():669-677. PubMed ID: 28039094
[TBL] [Abstract][Full Text] [Related]
17.
Higashi T; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Okina T; Suzuki N; Hasegawa H; Nagahama Y; Ishizu K; Oishi N; Kimura H; Watanabe H; Ono M; Saji H; Yamauchi H
Ann Nucl Med; 2018 Apr; 32(3):206-216. PubMed ID: 29388083
[TBL] [Abstract][Full Text] [Related]
18. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET.
Rosario BL; Weissfeld LA; Laymon CM; Mathis CA; Klunk WE; Berginc MD; James JA; Hoge JA; Price JC
Neuroimage; 2011 Apr; 55(3):933-41. PubMed ID: 21195782
[TBL] [Abstract][Full Text] [Related]
19. Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility.
Landt J; D'Abrera JC; Holland AJ; Aigbirhio FI; Fryer TD; Canales R; Hong YT; Menon DK; Baron JC; Zaman SH
Arch Neurol; 2011 Jul; 68(7):890-6. PubMed ID: 21403005
[TBL] [Abstract][Full Text] [Related]
20. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
Wang Y; Klunk WE; Debnath ML; Huang GF; Holt DP; Shao L; Mathis CA
J Mol Neurosci; 2004; 24(1):55-62. PubMed ID: 15314250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
